Abstract: An organic EL device includes an emitting region provided between a cathode and an anode, a first anode-side-organic layer, a second anode-side-organic layer, and a third anode-side-organic layer, in which the emitting region includes at least a first emitting layer, the first anode-side-organic layer is in direct contact with the second anode-side-organic layer, the second anode-side-organic layer is in direct contact with the third anode-side-organic layer, the third anode-side-organic layer has a film thickness of 20 nm or more, the second anode-side-organic layer contains at least one compound different from a compound contained in the third anode-side-organic layer, the first emitting layer is a fluorescent emitting layer, and a refractive index NM2 of a constituent material contained in the second anode-side-organic layer and a refractive index NM3 of a constituent material contained in the third anode-side-organic layer satisfy a relationship of Numerical Formula NM, NM2>NM3??(Numerical Formula NM

Abstract: An organic EL device includes: an emitting layer including a first emitting layer and a second emitting layer; and a hole transporting zone including at least two organic compound layers, in which a first organic compound layer of the hole transporting zone includes a first organic material and a second organic material that are mutually different, a content of the first organic material in the first organic compound layer is less than 10 mass %, the first emitting layer includes a first host material and a first emitting compound, the second emitting layer includes a second host material and a second emitting compound, and a triplet energy of the first host material T1(H1) and a triplet energy of the second host material T1(H2) satisfy a relationship of Numerical Formula 1, T1(H1)>T1(H2)??(Numerical Formula 1).

Abstract: An organic electroluminescence device includes: a first emitting layer disposed between an anode and a cathode; and a second emitting layer disposed between the first emitting layer and the cathode. The first emitting layer contains a first host material and a first emitting compound, and the second emitting layer contains a second host material and a second emitting compound. A triplet energy of the first host material T1(H1) and a triplet energy of the second host material T1(H2) satisfy the relationship of a Numerical Formula 1 (T1(H1)<T1(H2)), and a lowest unoccupied molecular orbital energy level of the second host material LUMO(H2) and a lowest unoccupied molecular orbital energy level of the second emitting compound LUMO(D2) satisfy the relationship of a Numerical Formula 2 (|LUMO(D2)|?|LUMO(H2)|<0.74 eV).

Abstract: An organic electroluminescence device includes an emitting region between a cathode and an anode, a first anode side organic layer, and a second anode side organic layer. The emitting region includes at least a first emitting layer, the first anode side organic layer is in direct contact with the second anode side organic layer, the first anode side organic layer contains first and second organic materials, a content of the first organic material in the first anode side organic layer is less than 50 mass %, the second anode side organic layer contains a second hole transporting zone material, the first emitting layer is an emitting layer that emits fluorescence, and a refractive index NM1 of the constituent materials contained in the first anode side organic layer and a refractive index NM2 of the constituent material contained in the second anode side organic layer satisfy a relationship of NM1>NM2.

Abstract: An organic EL device includes a first emitting layer and a second emitting layer, in which the first emitting layer contains a first host material, the second emitting layer contains a second host material, the first host material and the second host material are mutually different, the first emitting layer contains at least a first emitting compound that emits light with a maximum peak wavelength of 453 nm or less, the second emitting layer contains at least a second emitting compound that emits light with a maximum peak wavelength of 500 nm or less, the first emitting compound and the second emitting compound are mutually the same or different, and the triplet energy T1(H1) of the first host material and the triplet energy T1(H2) of the second host material satisfy a relationship of a numerical formula (Numerical Formula 1) below, T1(H1)>T1(H2)??(Numerical Formula 1).

Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.

Abstract: The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.